An ad-free and cookie-free webpage by FactorPad
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Laboratory Crp Of Amer Hldgs. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how LH stock compares to 2,000+ US-based stocks, and to peers in the Health Services sector and Services to the Health Industry industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Laboratory Corp. of America Holdings is a clinical laboratory company. The firm engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the following segments: LabCorp Diagnostics and Covance Drug Development. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment provides drug development solutions to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
This is a new resource, spread the word, tell a friend